mProX™ Human CD22 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD22 has various applications in cancer research and treatment. One application is in improving the cytotoxicity of chimeric antigen receptor (CAR)-T cell therapies against low-antigen cancers. By engineering CARs targeting CD22 and including intrinsically disordered regions (IDRs), CAR-T cells can exhibit enhanced membrane-proximal signaling, leading to increased release of cytotoxic factors and improved killing activity against low antigen-expressing cancer cells. This approach broadens the application of CAR-T therapy to cancers with low antigen expression. Another application of CD22 is in the normalization of small extracellular vesicle (sEV) cargo in human cancer. sEVs in the blood of cancer patients contain higher amounts of tumor markers, including miRNAs. CD22 can serve as a reliable endogenous control for measuring sEV-miRNA content, allowing for standardized and consistent measurements in cancer liquid biopsy. Additionally, CD22 is targeted in sequential CAR-T cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukemia. This approach involves initially infusing CD19-directed CAR T cells, followed by CD22-directed CAR T-cell infusion after achieving minimal residual disease-negative complete remission. This sequential strategy has shown deep and sustained responses with an acceptable toxicity profile, providing potential long-term benefits for children with this condition. However, it is important to note that there can be side effects associated with CAR-T cell therapy, such as cytomegalovirus (CMV) infection/reactivation. CMV infection can occur in patients long after receiving anti-CD19/22 CAR-T cell therapy and can induce fatal pneumonia. Therefore, monitoring and managing viral infections or reactivations is crucial in patients receiving CAR-T cell infusion. Finally, CD22 has also been studied in the context of the impact of the COVID-19 pandemic on the diagnosis of colorectal cancer within a population-based organized screening program. The pandemic resulted in delays in screening and colonoscopy, but it did not significantly reduce participation, adherence to colonoscopy, or the diagnostic yield of colonoscopy.